Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss treatments, such as minoxidil and finasteride, being replaced by verteporfin, with humorous responses.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

User on fin, minox, and ketoconazole seeks to add another topical anti-androgen. Hierarchy of effectiveness: 1. RU55841, 2. Fluridil - Eucapil, 3. CB-03-01 - Breezula, 4. Ketoconazole; alfatradiol suggested as addition.

Verteporfin human clinical trials for hair loss may start in 2025. Additional resources and presentations are available for more information.

The user has been using a combination of 0.3% topical finasteride, minoxidil, ketoconazole, and microneedling once a week for two months with positive results and no side effects. They apply the treatment daily using a spray and have short hair, which makes application easier.

Finasteride effectively treated hormonal acne for multiple users, including the original poster. Topical treatments like Winlevi are effective but expensive and not always covered by insurance.

The user is considering trying finasteride again for hair loss despite past side effects like tender nipples and concerns about mental health impacts. They are advised to consult a doctor and consider topical or low-dose finasteride.

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

PP405 is discussed as a potential alternative to finasteride, but its effectiveness and market availability are uncertain. Users share experiences with finasteride, minoxidil, and topical treatments, noting side effects and application techniques.

The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.

The user is experiencing hair loss after a hair transplant and is considering using fluridil (Eucapil) and possibly alfatradiol as treatments, as they couldn't tolerate finasteride or minoxidil. The manufacturer of Eucapil confirmed they won't produce higher concentrations due to lack of efficacy.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

The conversation discusses using verteporfin for hair regrowth and minimizing scarring after hair transplants. Some individuals plan to self-administer verteporfin, potentially in combination with microneedling, as an alternative to hair transplants.

Combining topical finasteride with RU58841 for hair loss treatment. Users discuss the effectiveness and potential side effects of oral and topical finasteride.

The user is seeking advice on maximizing hair growth while using oral finasteride, topical minoxidil, Nizoral, and microneedling, and is considering adding a laser diode cap, topical finasteride, retinol, and caffeine. Suggestions include using tretinoin with minoxidil for better absorption, switching to dutasteride, and considering RU58841 or pyrilutamide.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

The user shared progress in hair regrowth using oral finasteride, topical minoxidil, and ketoconazole shampoo every other day, noting no side effects from finasteride. They expressed satisfaction with the results and optimism for further improvement.

Rapamycin and metformin may have hair regeneration properties. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

A 28-year-old user shared their positive experience with hair loss treatment using 1mg oral finasteride daily, topical minoxidil nightly, and weekly dermapen sessions. They reported increased confidence despite minor side effects like dandruff and gray hair.

The user experienced high liver enzyme levels, possibly due to topical finasteride or supplements, and decided to stop using finasteride while continuing minoxidil. After stopping finasteride and supplements, liver levels returned to normal, suggesting finasteride or supplements might have been the cause.

Using a low dose of topical Tamoxifen effectively reduces gynecomastia caused by finasteride, with minimal side effects. The solution involves mixing Tamoxifen with ethanol and propylene glycol, applied daily to the chest.

A human trial involving verteporfin for hair regeneration, with the results showing some regrowth of 1-2 hairs in an area where a follicular unit was extracted. The conversation also suggested that future studies should involve higher doses and more frequent injections.

Exploring hair loss treatments, with a focus on Finasteride and RU58841 as well as other topical solutions like stemoxydine 5%. The user found that they were sensitive to both oral and topical finasteride, but remain optimistic about finding the right treatment.

The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.

Verteporfin is discussed as a potential treatment for hair regrowth, but skepticism exists about its effectiveness in regenerating extracted hair follicles. The conversation also mentions the possibility of needing a hair transplant by 2028.

The user seeks alternatives to Propylene Glycol (PG) for delivering topical finasteride due to scalp irritation. They consider using Propanediol 1,3 and ask for other suggestions.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

RU58841 is used without finasteride by some due to side effects, with mixed results. Users report combining RU58841 with minoxidil and adjusting finasteride doses to manage hair loss.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The user reported 4 months of using 0.5mg finasteride and 6 months of microneedling, Nizoral, and topical melatonin. They saw improvement on the left side but no improvement on the right side and are hesitant to start minoxidil.